Neonatal seizures: dialogues between clinic and bench.
Neonatal seizures are common and often reflect a severe underlying neurologic dysfunction in neonates. Phenobarbital remains the mainstay of treatment of neonatal seizures, however, but it is ineffective in many patients and has adverse profiles in cognition. Furthermore, gamma-aminobutyric acid is excitatory early in brain development; therefore, treatment of neonatal seizures with phenobarbital must be cautious. In this review, we highlight the substantial progress that has been made in animal studies, and translate these results to the treatment of seizures in human neonates.
Department of Pediatrics, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, 123 Ta-Pei Road, Niao Sung, Kaohsiung 833, Taiwan. huang_li@pie.com.tw
Li-Tung
LT
Huang
You-Lin
YL
Tain
Ming-Chi
MC
Lai
San-Nan
SN
Yang
D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects / Q000254:growth & development; D006801:Humans; D007231:Infant, Newborn; D010634:Phenobarbital / Q000009:adverse effects / Q000627:therapeutic use*; D012640:Seizures / Q000188:drug therapy* / Q000209:etiology; D057170:Translational Research, Biomedical
D000927:Anticonvulsants; D010634:Phenobarbital